Interchange Capital Partners LLC Raises Holdings in Novartis AG $NVS

Interchange Capital Partners LLC lifted its holdings in shares of Novartis AG (NYSE:NVS) by 77.9% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 3,521 shares of the company’s stock after acquiring an additional 1,542 shares during the period. Interchange Capital Partners LLC’s holdings in Novartis were worth $426,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of NVS. WPG Advisers LLC purchased a new stake in shares of Novartis during the first quarter worth about $25,000. Tsfg LLC boosted its position in Novartis by 366.0% in the first quarter. Tsfg LLC now owns 233 shares of the company’s stock valued at $26,000 after buying an additional 183 shares during the last quarter. GFG Capital LLC purchased a new stake in Novartis in the second quarter valued at approximately $26,000. Barrett & Company Inc. purchased a new stake in Novartis in the second quarter valued at approximately $31,000. Finally, MCF Advisors LLC boosted its position in Novartis by 66.0% in the second quarter. MCF Advisors LLC now owns 264 shares of the company’s stock valued at $32,000 after buying an additional 105 shares during the last quarter. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Novartis Trading Down 0.9%

Shares of NYSE:NVS opened at $130.48 on Monday. Novartis AG has a 12-month low of $96.06 and a 12-month high of $133.55. The company has a market capitalization of $275.64 billion, a PE ratio of 18.99, a PEG ratio of 1.82 and a beta of 0.64. The business has a 50 day moving average of $127.56 and a two-hundred day moving average of $119.60. The company has a current ratio of 0.82, a quick ratio of 0.62 and a debt-to-equity ratio of 0.53.

Analyst Ratings Changes

A number of equities research analysts recently commented on NVS shares. Weiss Ratings reiterated a “buy (b)” rating on shares of Novartis in a research report on Wednesday, October 8th. Morgan Stanley upgraded Novartis from an “underweight” rating to an “equal weight” rating and set a $123.00 target price on the stock in a research report on Friday, August 8th. Wall Street Zen upgraded Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 11th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Novartis in a research report on Thursday, August 21st. Finally, The Goldman Sachs Group reiterated a “sell” rating and issued a $118.00 target price (down previously from $119.00) on shares of Novartis in a research report on Friday, September 12th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $120.33.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.